SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Director/PDMR Shareholding

27 Mar 2025 10:25

RNS Number : 5017C
Rentokil Initial PLC
27 March 2025
 

Notification of transaction by a Person Discharging Managerial Responsibilities

 

Rentokil Initial plc (the 'Company') hereby announces that Andy Ransom, Chief Executive, a Person Discharging Managerial Responsibility, has exercised his award of 964,464 ordinary shares of 1 pence each in the Company granted under the Company Performance Share Plan 2006 (PSP) in March 2015.

The award, which vested in March 2018, would lapse this month if it remained unexercised.

453,914 of these shares have been sold to cover the tax and national insurance liability arising from the exercise at a price of £3.5633 per share, and the balance of shares has been retained.

The notification set out below is provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

 

Rachel Canham

Group General Counsel & Company Secretary

+44 (0)1293 858 000

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Andy Ransom

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Rentokil Initial plc

b)

 

LEI

 

549300VN4WV7Z6T14K68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 1p each

 

 

ISIN: GB00B082RF11

 

b)

 

Nature of the transaction

 

 

Exercise of options under the Performance Share Plan 2006 (883,906 nil-cost options, plus 80,558 shares in dividends equivalents).

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

Nil consideration

964,464

d)

 

Aggregated information

 

- Aggregated volume

 

- Total price

 

 

 

964,464

 

N/A

e)

 

Date of the transaction

 

2025-03-26

f)

 

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Andy Ransom

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Rentokil Initial plc

b)

 

LEI

 

549300VN4WV7Z6T14K68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 1p each

 

 

ISIN: GB00B082RF11

 

b)

 

Nature of the transaction

 

 

Part sale of shares to cover tax and NIC

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£3.5633

453,914

d)

 

Aggregated information

 

- Aggregated volume

 

- Total price

 

 

 

453,914

 

£1,617,431.76

e)

 

Date of the transaction

 

2025-03-26

f)

 

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGCGDXCSDDGUR
Date   Source Headline
10th Nov 20232:28 pmRNSDirector/PDMR Shareholding
3rd Nov 20234:26 pmRNSHolding(s) in Company
3rd Nov 20234:22 pmRNSDirector/PDMR Shareholding
1st Nov 202312:50 pmRNSHolding(s) in Company
31st Oct 202311:45 amRNSHolding(s) in Company
30th Oct 20233:03 pmRNSDirector/PDMR Shareholding
30th Oct 202311:55 amRNSCredit rating update
19th Oct 20237:00 amRNSQ3 Trading Update
2nd Oct 202311:35 amRNSBlock listing Interim Review
27th Sep 20232:35 pmRNSDirector/PDMR Shareholding
1st Aug 202312:42 pmRNSDirector/PDMR Shareholding
27th Jul 20237:00 amRNS2023 Interim Results
29th Jun 20239:00 amRNSNotice of Management Presentation
23rd Jun 20235:58 pmRNSDirector/PDMR Shareholding
19th May 20233:03 pmRNSDirector/PDMR Shareholding
12th May 20239:09 amRNSDirector/PDMR Shareholding
11th May 20239:17 amRNSResult of AGM
28th Apr 202310:55 amRNSHolding(s) in Company
21st Apr 20232:41 pmRNSDirector/PDMR Shareholding
20th Apr 20237:00 amRNSQ1 Trading Update
4th Apr 20239:37 amRNSAnnual Financial Report
3rd Apr 202310:08 amRNSBlock listing Interim Review
23rd Mar 20239:42 amRNSDirector/PDMR Shareholding
20th Mar 20234:47 pmRNSDirector/PDMR Shareholding
16th Mar 20237:05 amRNSDirectorate Change
16th Mar 20237:00 amRNSFinal Results
9th Mar 20239:23 amRNSDirector Declaration
27th Feb 20238:55 amRNSNotice of Management Presentation
9th Nov 20224:33 pmRNSDirector Declaration
1st Nov 20222:25 pmRNSCorrection: Q3 Trading Update
1st Nov 20227:00 amRNSQ3 Trading Update
31st Oct 20224:03 pmRNSTotal Voting Rights
24th Oct 20225:15 pmRNSHolding(s) in Company
21st Oct 20224:42 pmRNSHolding(s) in Company
20th Oct 202212:35 pmRNSHolding(s) in Company
19th Oct 202211:43 amRNSHolding(s) in Company
18th Oct 20225:22 pmRNSHolding(s) in Company
17th Oct 20226:07 pmRNSHolding(s) in Company
17th Oct 202211:51 amRNSHolding(s) in Company
14th Oct 20224:39 pmRNSHolding(s) in Company
14th Oct 20224:37 pmRNSHolding(s) in Company
14th Oct 20229:30 amRNSAdditional Listing
13th Oct 20225:42 pmRNSHolding(s) in Company
13th Oct 20223:05 pmRNSHolding(s) in Company
12th Oct 20221:53 pmRNSAcquisition of Terminix Completion
10th Oct 20221:57 pmRNSHolding(s) in Company
10th Oct 20221:52 pmRNSHolding(s) in Company
10th Oct 20221:38 pmRNSHolding(s) in Company
7th Oct 20226:10 pmRNSRentokil Initial
6th Oct 20222:23 pmRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.